Sometimes that's a particular disease state and sometimes it's a specific population demographic. But payers and health systems don't want general data, they want specific data about their population, Unni says. #REpharmaUSA

Despite Trump's DEI purge, CMS's Health Equity Index in star ratings and Enhancing Oncology Model are still online. #REpharmaUSA

By the way I'm learning all this from Joe Daley, President, Addison Whitney and Dorothy Linvill-Neal, Director, Nomenclature Development and Strategy, Regeneron.

Brand name confusion in pharma is a safety issue -- 33% of medication errors are caused by drug name confusion. That's why FDA and EMA get involved and have to approve names. In a completely separate process from the trademark process. #REpharmaUSA

Incidentally, this is the downside to using an app for Q&A. Makes it very easy to censor inconvenient questions.